Allogeneic Transplant in Multiple Myeloma: A Potential Renaissance in the Era of Novel Therapies?
Richardson P. Biol Blood Marrow Transplant. 2014 Jun 20. pii: S1083-8791(14)00363-2. doi: 10.1016/j.bbmt.2014.06.013. [Epub ahead of print].
Bendamustine for the treatment of multiple myeloma in first-line and relapsed-refractory settings: a review of clinical trial data.
Palumbo A et al. Leuk Lymphoma. 2014 Jun 27:1-9. [Epub ahead of print].
Second transplant as a standard for multiple myeloma.
McCarthy PL. Lancet Oncol. 2014 Jun 16. pii: S1470-2045(14)70279-7. doi: 10.1016/S1470-2045(14)70279-7. [Epub ahead of print].
Bendamustine for the treatment of multiple myeloma in the first-line and relapsed-refractory settings: a review of the clinical trial data.
Palumbo A et al. Leuk Lymphoma. 2014 Jun 2:1-23. [Epub ahead of print].
A de novo monoclonal immunoglobulin deposition disease in a kidney transplant recipient: a case report.
Savenkoff B et al. J Med Case Rep. 2014 Jun 18;8(1):205. [Epub ahead of print].
Diagnosed hematological malignancies in Bangladesh – a retrospective analysis of over 5000 cases from 10 specialized hospitals.
Hossain MS et al. BMC Cancer. 2014 Jun 14;14(1):438. doi: 10.1186/1471-2407-14-438.
Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma.
Kim SS et al. Cytotherapy. 2014 Jun 10. pii: S1465-3249(14)00601-X. doi: 10.1016/j.jcyt.2014.05.003. [Epub ahead of print].
The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma.
Wu W et al. Br J Cancer. 2014 Jun 12. doi: 10.1038/bjc.2014.307. [Epub ahead of print].
A Home-Care, early discharge model after autrografting in Multiple Myeloma: results of a three-arm prospective, non-randomized study.
Martino M et al. Leuk Lymphoma. 2014 Jun 10:1-10. [Epub ahead of print].
Acquired von Willebrand disease and multiple myeloma: a case report of a breast cancer survivor.
Jin N et al. Blood Coagul Fibrinolysis. 2014 Jun 6. [Epub ahead of print].
AKT as a therapeutic target in multiple myeloma.
Keane NA et al. Expert Opin Ther Targets. 2014 Jun 6:1-19. [Epub ahead of print].
Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S et al. Expert Opin Investig Drugs. 2014 Jun 6:1-17. [Epub ahead of print].
Nonparametric Variable Selection for Predictive Models and Subpopulations in Clinical Trials.
Zhu J et al. J Biopharm Stat. 2014 Jun 6. [Epub ahead of print].
Cancer in British vegetarians: updated analyses of 4998 incident cancers in a cohort of 32,491 meat eaters, 8612 fish eaters, 18,298 vegetarians, and 2246 vegans.
Key TJ et al. Am J Clin Nutr. 2014 Jun 4;100(Supplement 1):378S-385S. [Epub ahead of print].
The future of autologous stem cell transplantation in myeloma.
van Rhee F et al. Blood. 2014 Jun 3. pii: blood-2014-03-561985. [Epub ahead of print].
Perceived need for information of patients with haematological malignancies: a literature review.
Rood JA et al. J Clin Nurs. 2014 Jun 3. doi: 10.1111/jocn.12630. [Epub ahead of print].
Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma.
Zabora J et al. Palliat Support Care. 2014 Jun 24:1-10. [Epub ahead of print].
Best Treatment Strategies in High-Risk Multiple Myeloma: Navigating a Gray Area.
Bianchi G et al. J Clin Oncol. 2014 Jun 2. pii: JCO.2014.55.7900. [Epub ahead of print].
Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide.
Morris C et al. Transfusion. 2014 Jun 26. doi: 10.1111/trf.12759. [Epub ahead of print].
Coexisting glomerular IgA deposition and IgG-kappa multiple myeloma.
Wang F et al. Ren Fail. 2014 Jun 24:1-3. [Epub ahead of print